Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 30, 2018

Primary Completion Date

September 30, 2020

Study Completion Date

May 27, 2021

Conditions
Squamous Non-Small Cell Lung Cancer
Interventions
DRUG

Avelumab

Participants received avelumab intravenous infusions at a dose of 800 milligram (mg) on Day 1 and Day 8 of each 3-week cycle for the first 4 cycles. Thereafter, administered every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.

DRUG

Cetuximab

Participants received cetuximab intravenous infusions at a dose of 250 milligram per meter square (mg/m\^2) body surface area on Day 1 and 500 mg/m\^2 body surface area on Day 8 of first 4 cycles of concurrent chemotherapy. Thereafter, administered given at a dose of 500 mg/m\^2 intravenous every 2 weeks in the Maintenance phase, until disease progression or unacceptable toxicities.

DRUG

Gemcitabine

Participants received gemcitabine intravenous infusions at a dose of 1250 mg/m\^2 body surface area on Day 1 and Day 8 in 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.

DRUG

Cisplatin

Participants received cisplatin intravenous infusions at a dose of 75 mg/m\^2 body surface area on Day 1 of 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.

DRUG

Carboplatin

In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles.

Trial Locations (20)

1125

Semmelweis Egyetem - Pulmonologiai Klinika, Budapest

2045

Tudogyogyintezet Torokbalint - Onkopulmonologiai es Jarobeteg centrum, Törökbálint

4032

Debreceni Egyetem - Tudogyogyaszati Klinika, Debrecen

8900

Zala Megyei Szent Rafael Korhaz, Zalaegerszeg

9024

Petz Aladar Megyei Oktato Korhaz - Pulmonologiai Osztaly, Győr

9700

Markusovszky Egyetemi Oktatokorhaz, Szombathely

15006

Complejo Hospitalario Universitario A Coruña - Servicio de Oncologia, A Coruña

28007

Hospital General Universitario Gregorio Marañon - Servicio de Oncologia Medica, Madrid

28041

Hospital Universitario 12 de Octubre - Servicio de Oncologia, Madrid

28050

Hospital Universitario HM Madrid Sanchinarro - Servicio de Oncologia, Madrid

29010

Hospital Regional Universitario de Malaga, Málaga

41009

Hospital Universitario Virgen Macarena - Servicio de Oncologia, Seville

46026

Hospital Universitari i Politecnic La Fe - Servicio de Oncologia Medica, Valencia

50009

Hospital Clinico Universitario Lozano Blesa - Dept of Oncology, Zaragoza

Unknown

"Clinical Center Bezanijska kosa - Department of Oncology", Belgrade

Clinical Center Kragujevac (no dept.), Belgrade

Institute for Pulmonary Diseases of Vojvodina, Kamenitz

Hospital Universitario Virgen del Rocio, Seville

08028

Hospital Universitari Quiron Dexeus - Servicio de Oncologia Medica, Barcelona

08035

Hospital Universitari Vall d'Hebron - Dept of Oncology, Barcelona

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03717155 - Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC | Biotech Hunter | Biotech Hunter